#South Korea #Seongnam #Rejuran #PharmaResearch #VIVACY

PharmaResearch Expands European Footprint with VIVACY Partnership

Introduction

PharmaResearch, a renowned player in the regenerative medicine sector, has recently made headlines with its strategic partnership agreement with VIVACY, a leading French medical aesthetics company. This agreement aims to bolster the distribution and visibility of PharmaResearch's innovative product, 'Rejuran', across the European market.

Details of the Partnership

Announced on August 29, 2025, PharmaResearch's collaboration with VIVACY will facilitate the distribution of 'Rejuran', based on Polynucleotide technology, in 22 European countries. Some key markets included in this partnership are the United Kingdom, Germany, and France. The agreement, valued at approximately EUR 54.5 million over a span of 5 years, represents a significant investment in PharmaResearch’s ambitions to establish a stronger presence in Europe.

VIVACY has proven itself as a formidable player in the medical aesthetics industry, boasting a robust distribution network backed by a wealth of marketing expertise. By leveraging VIVACY's established relationships and reputation, PharmaResearch is well-positioned to accelerate its introduction of 'Rejuran' to a wider audience.

The Vision for 'Rejuran'

CEO Jihoon Sohn of PharmaResearch emphasized the uniqueness of 'Rejuran' as the only PN-based medical device that has received approval under the EU Medical Device Regulation (MDR). He expressed optimism about the product's capacity to enhance skin rejuvenation and the company's overall visibility in the competitive landscape of medical aesthetics.

Sohn noted, “We are confident that this partnership will not only elevate 'Rejuran's profile but also strengthen its status as a leading skin booster brand internationally.”

VIVACY's Commitment to Excellence

On VIVACY’s side, their CEO, Bertrand, echoed similar sentiments. He pointed out the alignment of the premium nature of 'Rejuran' with VIVACY's commitment to offering excellence in medical solutions. Bertrand remarked on the combination of Rejuran’s quality and VIVACY's scientific reputation as an ideal recipe for success in the European market.

The Impact of the Agreement

This strategic distribution deal not only marks a new chapter for PharmaResearch but also signifies a pivotal advancement in regenerative aesthetics across Europe. With plans for a phased rollout beginning shortly, practitioners and patients alike can expect to access advanced solutions in skin regeneration.

The Companies Behind the Partnership

PharmaResearch emanates from South Korea and is dedicated to improving life quality through innovative regenerative medicine. Their diverse portfolio includes medical devices, supplements, and cosmetics, with a focus on proprietary compounds such as DOT™ PDRN and DOT™ PN. The firm's headquarters is located in Gangneung-si, Gangwon-do, South Korea, with facilities extending to the USA.

In contrast, Laboratoires VIVACY, founded in 2007, has carved its niche in regenerative aesthetics with remarkable products like STYLAGE® dermal fillers. Headquartered in Paris, VIVACY is celebrated for its cutting-edge IPN-Like Technology, delivering exceptional results in aesthetic procedures.

Conclusion

This partnership between PharmaResearch and VIVACY represents a forward-thinking alliance that paves the way for enhanced access and use of innovative medical solutions in Europe. As 'Rejuran' prepares for its imminent launch across several countries, stakeholders in the aesthetics field will be keenly observing the partnership's impact on both patients’ experiences and market dynamics.